The contribution of chronic kidney disease to the global burden of major noncommunicable diseases (Q57701988)

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

The global challenge of chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Expanding priorities--confronting chronic disease in countries with low income

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Has the incidence of end-stage renal disease in the USA and other countries stabilized?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Chronic kidney disease in the developing world.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Combining GFR and albuminuria to classify CKD improves prediction of ESRD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Diagnosing chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

A new equation to estimate glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

The KDOQI 2002 classification of chronic kidney disease: for whom the bell tolls

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Challenging chronic kidney disease: experience from chronic kidney disease prevention programs in Shanghai, Japan, Taiwan and Australia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Prevalence of chronic kidney disease in an urban Mexican population

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

United States Renal Data System 2008 Annual Data Report

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Kidney early evaluation program: a community-based screening approach to address disparities in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Burden of CKD, proteinuria, and cardiovascular risk among Chinese, Mongolian, and Nepalese participants in the International Society of Nephrology screening programs

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Prenatal programming-effects on blood pressure and renal function

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Prevalence of chronic kidney disease in the United States

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Chronic kidney disease, diabetes, and hypertension: what's in a name?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Relation between kidney function, proteinuria, and adverse outcomes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Chronic kidney disease and mortality risk: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Cardiovascular disease in children with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: role of calcium-phosphorus metabolism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Cardiovascular disease in pediatric chronic dialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Low level of self-reported physical activity in ambulatory patients new to dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Early recognition and prevention of chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Chronic kidney disease: the global challenge

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

The association of poverty with the prevalence of albuminuria: data from the Third National Health and Nutrition Examination Survey (NHANES III).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Area socioeconomic status and progressive CKD: the Atherosclerosis Risk in Communities (ARIC) Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Socioeconomic status and chronic kidney disease at presentation to a renal service in the United Kingdom

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Socio-economic status and chronic renal failure: a population-based case-control study in Sweden.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Geographic, ethnic, age-related and temporal variation in the incidence of end-stage renal disease in Europe, Canada and the Asia-Pacific region, 1998-2002

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Geographical patterns of end-stage renal disease incidence and risk factors in rural and urban areas of South Carolina

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Individual and neighborhood socioeconomic status and progressive chronic kidney disease in an elderly population: The Cardiovascular Health Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Socioeconomic status and end-stage renal disease in the United States

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

CKD prevention in Sub-Saharan Africa: a call for governmental, nongovernmental, and community support

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Prevalence of chronic kidney disease in the Kidney Early Evaluation Program (KEEP) México and comparison with KEEP US.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

The risk of acute renal failure in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Acute kidney injury, mortality, length of stay, and costs in hospitalized patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Incidence and outcomes of acute kidney injury in a referred chronic kidney disease cohort

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Early detection of CKD: the benefits, limitations and effects on prognosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

A public health action plan is needed for chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Global and societal implications of the diabetes epidemic

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

World Kidney Day 2010: diabetic kidney disease--act now or pay later

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Limited knowledge of kidney disease in a survey of AusDiab study participants.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Projecting the future diabetes population size and related costs for the U.S.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Comparison of different measures of urinary protein excretion for prediction of renal events

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Cardiac disease in diabetic end-stage renal disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Undiagnosed renal impairment in patients with and without diabetes with normal serum creatinine undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

The management of diabetic neuropathy in CKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Effect of a multifactorial intervention on mortality in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Preventing microalbuminuria in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Reduction in natural death and renal failure from a systematic screening and treatment program in an Australian Aboriginal community

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

A chronic disease outreach program for Aboriginal communities

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Prevention of chronic renal failure at the community level

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Experience with a program for prevention of chronic renal failure in India

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Nephrologists sans frontières: preventing chronic kidney disease on a shoestring

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

The kidney in hypertension--villain and victim

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Global burden of hypertension: analysis of worldwide data

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Waist-to-hip ratio, body mass index, and subsequent kidney disease and death.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

World Kidney Day: hypertension and chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Urinary albumin excretion as a predictor of the development of hypertension in the general population

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

GFR, proteinuria and circadian blood pressure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Hypertension, chronic kidney disease, and the development of cardiovascular risk: a joint primacy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Hypertension awareness, treatment, and control in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999-2006

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Strict blood-pressure control and progression of renal failure in children

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Strategies for national health care systems in emerging countries: the case of screening and prevention of renal disease progression in Bolivia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

The contribution of the Framingham Heart Study to the prevention of cardiovascular disease: a global perspective

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Cardiovascular disease and subsequent kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Cor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Racial differences in mortality among those with CKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Differences in progression of CKD and mortality amongst Caucasian, Oriental Asian and South Asian CKD patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Impact of kidney disease and blood pressure on the development of cardiovascular disease: an overview from the Japan Arteriosclerosis Longitudinal Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Proteinuria and Stroke: A Meta-analysis of Cohort Studies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Albuminuria in chronic heart failure: prevalence and prognostic importance

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Screening for CKD and cardiovascular disease risk factors using mobile clinics in Jalisco, Mexico

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Population based screening for chronic kidney disease: cost effectiveness study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

The combined contribution of albuminuria and glomerular filtration rate to the prediction of cardiovascular mortality in elderly men.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Urinary albumin excretion, even within the normal range, predicts an increase in left ventricular mass over the following 5 years.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trøndelag Health Study (HUNT), Norway

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Low-Grade Albuminuria and the Risks of Hypertension and Blood Pressure Progression

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

The case for using albuminuria in staging chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Screening for microalbuminuria in the general population: a tool to detect subjects at risk for progressive renal failure in an early phase?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Selection on albuminuria enhances the efficacy of screening for cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Extended prognostic value of urinary albumin excretion for cardiovascular events

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Screening for albuminuria identifies individuals at increased renal risk

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Rapid decline of kidney function increases cardiovascular risk in the elderly

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Supramaximal dose of candesartan in proteinuric renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of r

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Role of remission clinics in the longitudinal treatment of CKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Evaluation of measures of urinary albumin excretion

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Prevalence of chronic kidney disease in elderly patients with normal serum creatinine levels undergoing percutaneous coronary interventions.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Renal insufficiency and mortality in patients with known or suspected coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Are we ready to screen the general population for microalbuminuria?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Taking a public health approach to the prevention of end-stage renal disease: the NKF Singapore Program

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Epidemiology, impact and preventive care of chronic kidney disease in Taiwan

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

A new initiative in nephrology: 'Kidney disease: improving global outcomes'.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Kidney disease: improving global outcomes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Screening for chronic kidney disease in emerging countries: feasibility and hurdles

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Prevention programmes of progressive renal disease in developing nations

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021

Status of chronic kidney disease prevention programs: International Federation of Kidney Foundation Members 2005/2007.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.368

7 January 2021